Print Friendly, PDF & Email

NCT/Study#

NCT04471844 /

EF-32

EF-32 (TRIDENT): A Pivotal Randomized, Open-Label Study Of Optune® (Ttfields, 200khz) Concomitant With Radiation Therapy And Temozolomide For The Treatment Of Actively Diagnosed Glioblastoma

DISEASE GROUP:
Neuro-Oncology
current phase:
NA
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: